← All trials
NCT00138294
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 1998
- Primary completion
- Jun 1, 2010
- Completion date
- Jun 1, 2010
- First posted
- —
- Last posted
- —
- Enrollment
- 29255
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Baylor UniversityLead sponsor
- Scott and White HealthcareCollaborator
- Baylor UniversityOverall official - principal investigator
- Baylor UniversityReponsible party - principal investigator
- NovartisCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Sanofi-AventisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.